Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial
- PMID: 29514235
- PMCID: PMC5850547
- DOI: 10.1093/cid/cix1142
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial
Abstract
Background: Severely immunocompromised human immunodeficiency virus (HIV)-infected individuals have high mortality shortly after starting antiretroviral therapy (ART). We investigated predictors of early mortality and "late presenter" phenotypes.
Methods: The Reduction of EArly MortaLITY (REALITY) trial enrolled ART-naive adults and children ≥5 years of age with CD4 counts <100 cells/µL initiating ART in Uganda, Zimbabwe, Malawi, and Kenya. Baseline predictors of mortality through 48 weeks were identified using Cox regression with backwards elimination (exit P > .1).
Results: Among 1711 included participants, 203 (12%) died. Mortality was independently higher with older age; lower CD4 count, albumin, hemoglobin, and grip strength; presence of World Health Organization stage 3/4 weight loss, fever, or vomiting; and problems with mobility or self-care at baseline (all P < .04). Receiving enhanced antimicrobial prophylaxis independently reduced mortality (P = .02). Of five late-presenter phenotypes, Group 1 (n = 355) had highest mortality (25%; median CD4 count, 28 cells/µL), with high symptom burden, weight loss, poor mobility, and low albumin and hemoglobin. Group 2 (n = 394; 11% mortality; 43 cells/µL) also had weight loss, with high white cell, platelet, and neutrophil counts suggesting underlying inflammation/infection. Group 3 (n = 218; 10% mortality) had low CD4 counts (27 cells/µL), but low symptom burden and maintained fat mass. The remaining groups had 4%-6% mortality.
Conclusions: Clinical and laboratory features identified groups with highest mortality following ART initiation. A screening tool could identify patients with low CD4 counts for prioritizing same-day ART initiation, enhanced prophylaxis, and intensive follow-up.
Clinical trials registration: ISRCTN43622374.
Figures

Similar articles
-
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822. N Engl J Med. 2017. PMID: 28723333 Free PMC article. Clinical Trial.
-
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141. Clin Infect Dis. 2018. PMID: 29514234 Free PMC article. Clinical Trial.
-
Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.Lancet HIV. 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Lancet HIV. 2018. PMID: 29653915 Free PMC article. Clinical Trial.
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e. AIDS. 2010. PMID: 20613459 Free PMC article. Clinical Trial.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
Cited by
-
Inflammatory biomarkers prior to antiretroviral therapy as prognostic markers of 12-month mortality in South Africa and Uganda.AIDS. 2019 Nov 1;33(13):2043-2048. doi: 10.1097/QAD.0000000000002305. AIDS. 2019. PMID: 31274541 Free PMC article.
-
Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study.Front Med (Lausanne). 2024 Feb 28;11:1302710. doi: 10.3389/fmed.2024.1302710. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38482527 Free PMC article.
-
Association between admission serum albumin and 12-weeks mortality in patients with late AIDS/HIV diagnosis: a retrospective cohort study.Sci Rep. 2024 Aug 9;14(1):18487. doi: 10.1038/s41598-024-69282-x. Sci Rep. 2024. PMID: 39122884 Free PMC article.
-
Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study.BMC Cancer. 2023 Sep 21;23(1):890. doi: 10.1186/s12885-023-11402-3. BMC Cancer. 2023. PMID: 37735371 Free PMC article.
-
Late cART Initiation Consistently Driven by Late HIV Presentation: A Multicenter Retrospective Cohort Study in Taiwan from 2009 to 2019.Infect Dis Ther. 2022 Jun;11(3):1033-1056. doi: 10.1007/s40121-022-00619-7. Epub 2022 Mar 18. Infect Dis Ther. 2022. PMID: 35301666 Free PMC article.
References
-
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach 2nd ed 2016. Available at: http://www.who.int/hiv/pub/arv/arv-2016/en/. Accessed 13 January 2018.
-
- TEMPRANO ANRS Study Group , Danel C, Moh R, Gabillard D et al. . A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808–22. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- MC_UU_12023/17/MRC_/Medical Research Council/United Kingdom
- MR/M007367/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_12023/23/MRC_/Medical Research Council/United Kingdom
- MC_UU_12023/26/MRC_/Medical Research Council/United Kingdom
- MC_EX_G1100693/MRC_/Medical Research Council/United Kingdom
- U01 AI069911/AI/NIAID NIH HHS/United States
- 108065/Z/15/Z/WT_/Wellcome Trust/United Kingdom
- 101113/Z/13/Z/WT_/Wellcome Trust/United Kingdom
- G1100693/MRC_/Medical Research Council/United Kingdom
- 203077/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- MC_EX_UU_G1100693/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- MR/P022251/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials